Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001
| Autor: | Marie-Antoinette Piens, Florence Persat, S. Picot, D. Martin |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Microbiology (medical) medicine.medical_specialty Microbiology law.invention Medical microbiology law Intensive care Bacteriology Humans Medicine Mycosis Fungemia Aged Candida business.industry Candidiasis General Medicine Middle Aged bacterial infections and mycoses medicine.disease Intensive care unit Corpus albicans Surgery Infectious Diseases Female France business Hospital Units Fluconazole medicine.drug |
| Zdroj: | European Journal of Clinical Microbiology & Infectious Diseases. 24:329-333 |
| ISSN: | 1435-4373 0934-9723 |
| DOI: | 10.1007/s10096-005-1321-y |
| Popis: | In order to determine the types of Candida spp. isolated from bloodstream cultures in Lyon, France, a retrospective study of isolates collected at five different bacteriology laboratories from 1998 to 2001 was conducted. During this period Candida spp. were isolated from 190 patients hospitalized in the internal medicine (32%), hematology (23%) and surgery (23%) wards, and in intensive care units (22%). C. albicans was the leading cause of Candida infection (49.5%), followed by C. glabrata (12.6%) and C. parapsilosis (12.1%). Among the onco-hematology patients, the major cause of candidemia was C. krusei (34%), followed by C. albicans (19%), while these two species were identified in 4% and 59% of patients in the other wards, respectively. In the single onco-hematology ward that was specialized in treating acute myeloid leukemia, 14 C. krusei isolates were identified in this study, which contrasts with the single C. krusei isolate recorded between 1992 and 1996. Since C. krusei has inherent resistance to the antifungal agent fluconazole, prophylactic use of fluconazole in these patients was investigated, but no relationship between these two parameters was found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink